Sight Sciences (NASDAQ:SGHT) Reaches New 52-Week High on Analyst Upgrade

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) reached a new 52-week high during mid-day trading on Thursday after UBS Group raised their price target on the stock from $8.00 to $13.50. UBS Group currently has a buy rating on the stock. Sight Sciences traded as high as $11.32 and last traded at $11.3340, with a volume of 104,735 shares trading hands. The stock had previously closed at $10.92.

Other research analysts have also recently issued reports about the company. HC Wainwright started coverage on Sight Sciences in a research note on Thursday, October 15th. They set a “buy” rating and a $14.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price (up from $9.00) on shares of Sight Sciences in a research note on Thursday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a report on Wednesday, November 4th. Citigroup raised their price target on Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Finally, Wall Street Zen raised Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.31.

View Our Latest Stock Report on Sight Sciences

Insider Activity

In other Sight Sciences news, EVP Brenton Taylor sold 2,988 shares of the business’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total value of $26,443.80. Following the transaction, the executive vice president owned 261,990 shares in the company, valued at approximately $2,318,611.50. The trade was a 1.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO David Badawi sold 7,797 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the transaction, the chief technology officer directly owned 1,975,075 shares of the company’s stock, valued at approximately $17,874,428.75. This trade represents a 0.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 47,646 shares of company stock worth $429,157. 30.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Sight Sciences during the second quarter valued at approximately $16,710,000. Royce & Associates LP bought a new stake in Sight Sciences in the third quarter valued at $1,676,000. GSA Capital Partners LLP bought a new stake in Sight Sciences in the second quarter valued at $908,000. Bank of America Corp DE bought a new stake in Sight Sciences in the second quarter valued at $520,000. Finally, Bank of New York Mellon Corp purchased a new position in Sight Sciences during the 2nd quarter valued at $495,000. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Trading Down 1.5%

The company has a debt-to-equity ratio of 0.71, a quick ratio of 4.72 and a current ratio of 5.04. The stock’s 50-day simple moving average is $8.97 and its 200-day simple moving average is $6.20. The firm has a market capitalization of $601.93 million, a PE ratio of -20.83 and a beta of 2.44.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $24.92 million during the quarter, compared to analysts’ expectations of $23.55 million. Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 43.91%. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -0.48 EPS for the current fiscal year.

About Sight Sciences

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Featured Articles

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.